Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma

Journal of Neuro-oncology
Jennie W TaylorAndrew S Chi


Tumor cell infiltration is a major mechanism of treatment escape in glioblastoma. Src is an intracellular tyrosine kinase that mediates tumor cell motility and invasiveness. We evaluated the efficacy and safety of bosutinib, a tyrosine kinase inhibitor that potently inhibits Src and Abl, in patients with recurrent glioblastoma. In this two-arm study, patients with histologically confirmed recurrent glioblastoma and ≤2 relapses, not previously treated with anti-vascular endothelial growth factor (VEGF) therapy, were administered oral bosutinib 400 mg daily. Arm A planned for 6 patients who were candidates for surgical resection to be given bosutinib for 7-9 days prior to resection. Arm B was a two-stage design phase 2 trial targeting 30 patients. The primary endpoint was progression-free survival at 6 months (PFS6) in Arm B. After 9 patients enrolled onto stage 1 of Arm B, 9 (100 %) patients progressed within 6 months. Therefore, the study met the pre-specified criteria for early closure and both Arms were closed. In Arm B, Median PFS was 7.71 weeks and median OS was 50 weeks. Best objective response was stable disease in one patient (11.1 %). Seven patients (77.8 %) had treatment-related AEs of any grade and 2 (22.2 %) were gra...Continue Reading

Associated Clinical Trials


Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ Gregory Cairncross
Mar 1, 1989·Controlled Clinical Trials·R Simon
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T WongW K Alfred Yung
Jul 23, 2002·Nature Cell Biology·Egle AvizienyteMargaret C Frame
Mar 11, 2005·The New England Journal of Medicine·Roger StuppNational Cancer Institute of Canada Clinical Trials Group
Mar 23, 2006·Journal of Neuro-oncology·Caren V LundBrian P Eliceiri
Dec 24, 2008·Journal of Clinical Psychology in Medical Settings·Suzanne Bennett Johnson
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jun 30, 2009·Journal of Neuro-oncology·Andrew D NordenPatrick Y Wen
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy F Cloughesy
Dec 15, 2010·Journal of Neuro-oncology·C Lu-EmersonP Y Wen
Dec 20, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adil I DaudWells A Messersmith
Mar 13, 2012·Journal of Neuro-oncology·David A ReardonHenry S Friedman
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini
Mar 5, 2013·PloS One·Deborah HuveldtPanos Z Anastasiadis
May 16, 2013·Biologics : Targets & Therapy·Gunhild Keller-von Amsberg, Philippe Schafhausen


Jul 15, 2015·Oncology Letters·Quanchi ChenZhengdong Cai
Jul 15, 2016·Journal of Medicinal Chemistry·Timothy P Heffron
Jan 20, 2017·CNS Drugs·Mayur M Patel, Bhoomika M Patel
Dec 19, 2017·Journal of Drug Targeting·Khaled GreishHayley Nehoff
Apr 3, 2020·Archives of Pharmacal Research·Gayoung Kim, Young Tag Ko
Jun 18, 2020·Cancers·Claudia CirottiDaniela Barilà
Jun 16, 2017·American Journal of Physiology. Renal Physiology·Jun Wang, Shougang Zhuang
Nov 9, 2020·Critical Reviews in Oncology/hematology·Camille HouronCosmin Sebastian Voican

Related Concepts

Aniline Compounds
Antineoplastic Agents
Brain Tumor, Recurrent
Glioblastoma Multiforme
Neoplasm Recurrence, Local
Cox Proportional Hazards Models
Progression-Free Survival

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.